Number of hypoglycemic drugs in the regimens: monotherapy regimen was 50.3% (including of 29.3% insulin, 11.2% metformin and 9.8% gliclazid); the regimen of two hypoglycemic drugs were 38.1% (combination with gliclazid was the highest 17.6%) and the regimens of three hypoglycemic drugs were 9.3% (combination metformin with gliclazid and insulin was the highest 9.3%).